Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Cancer API Market

ID: MRFR/Pharma/4782-CR
128 Pages
Rahul Gotadki
Last Updated: January 13, 2026

Cancer API Market Research Report Information by Drug Type (Innovative Oncology API, And Generic Oncology API), By Manufacturer Type (Captive Manufacturer, Merchant Manufacturer), By Type Of Synthesis (Synthetic Oncology Apis, And Biotech Oncology API), By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Stomach Cancer, Liver Cancer, Cervical Cancer, And Others), and by Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Cancer API Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Drug Type (USD Billion)
  49.     4.1.1 Innovative Oncology APIs
  50.     4.1.2 Generic Oncology APIs
  51.   4.2 Healthcare, BY Manufacturer Type (USD Billion)
  52.     4.2.1 Captive Manufacturer
  53.     4.2.2 Merchant Manufacturer
  54.   4.3 Healthcare, BY Type of Synthesis (USD Billion)
  55.     4.3.1 Synthetic Oncology APIs
  56.     4.3.2 Biotech Oncology APIs
  57.   4.4 Healthcare, BY Indication (USD Billion)
  58.     4.4.1 Lung Cancer
  59.     4.4.2 Breast Cancer
  60.     4.4.3 Colorectal Cancer
  61.     4.4.4 Prostate Cancer
  62.     4.4.5 Stomach Cancer
  63.     4.4.6 Liver Cancer
  64.     4.4.7 Cervical Cancer
  65.     4.4.8 Others
  66.   4.5 Healthcare, BY Region (USD Billion)
  67.     4.5.1 North America
  68.       4.5.1.1 US
  69.       4.5.1.2 Canada
  70.     4.5.2 Europe
  71.       4.5.2.1 Germany
  72.       4.5.2.2 UK
  73.       4.5.2.3 France
  74.       4.5.2.4 Russia
  75.       4.5.2.5 Italy
  76.       4.5.2.6 Spain
  77.       4.5.2.7 Rest of Europe
  78.     4.5.3 APAC
  79.       4.5.3.1 China
  80.       4.5.3.2 India
  81.       4.5.3.3 Japan
  82.       4.5.3.4 South Korea
  83.       4.5.3.5 Malaysia
  84.       4.5.3.6 Thailand
  85.       4.5.3.7 Indonesia
  86.       4.5.3.8 Rest of APAC
  87.     4.5.4 South America
  88.       4.5.4.1 Brazil
  89.       4.5.4.2 Mexico
  90.       4.5.4.3 Argentina
  91.       4.5.4.4 Rest of South America
  92.     4.5.5 MEA
  93.       4.5.5.1 GCC Countries
  94.       4.5.5.2 South Africa
  95.       4.5.5.3 Rest of MEA
  96. 5 SECTION V: COMPETITIVE ANALYSIS
  97.   5.1 Competitive Landscape
  98.     5.1.1 Overview
  99.     5.1.2 Competitive Analysis
  100.     5.1.3 Market share Analysis
  101.     5.1.4 Major Growth Strategy in the Healthcare
  102.     5.1.5 Competitive Benchmarking
  103.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  104.     5.1.7 Key developments and growth strategies
  105.       5.1.7.1 New Product Launch/Service Deployment
  106.       5.1.7.2 Merger & Acquisitions
  107.       5.1.7.3 Joint Ventures
  108.     5.1.8 Major Players Financial Matrix
  109.       5.1.8.1 Sales and Operating Income
  110.       5.1.8.2 Major Players R&D Expenditure. 2023
  111.   5.2 Company Profiles
  112.     5.2.1 Roche (CH)
  113.       5.2.1.1 Financial Overview
  114.       5.2.1.2 Products Offered
  115.       5.2.1.3 Key Developments
  116.       5.2.1.4 SWOT Analysis
  117.       5.2.1.5 Key Strategies
  118.     5.2.2 Novartis (CH)
  119.       5.2.2.1 Financial Overview
  120.       5.2.2.2 Products Offered
  121.       5.2.2.3 Key Developments
  122.       5.2.2.4 SWOT Analysis
  123.       5.2.2.5 Key Strategies
  124.     5.2.3 Bristol-Myers Squibb (US)
  125.       5.2.3.1 Financial Overview
  126.       5.2.3.2 Products Offered
  127.       5.2.3.3 Key Developments
  128.       5.2.3.4 SWOT Analysis
  129.       5.2.3.5 Key Strategies
  130.     5.2.4 Merck & Co. (US)
  131.       5.2.4.1 Financial Overview
  132.       5.2.4.2 Products Offered
  133.       5.2.4.3 Key Developments
  134.       5.2.4.4 SWOT Analysis
  135.       5.2.4.5 Key Strategies
  136.     5.2.5 Amgen (US)
  137.       5.2.5.1 Financial Overview
  138.       5.2.5.2 Products Offered
  139.       5.2.5.3 Key Developments
  140.       5.2.5.4 SWOT Analysis
  141.       5.2.5.5 Key Strategies
  142.     5.2.6 AstraZeneca (GB)
  143.       5.2.6.1 Financial Overview
  144.       5.2.6.2 Products Offered
  145.       5.2.6.3 Key Developments
  146.       5.2.6.4 SWOT Analysis
  147.       5.2.6.5 Key Strategies
  148.     5.2.7 Pfizer (US)
  149.       5.2.7.1 Financial Overview
  150.       5.2.7.2 Products Offered
  151.       5.2.7.3 Key Developments
  152.       5.2.7.4 SWOT Analysis
  153.       5.2.7.5 Key Strategies
  154.     5.2.8 Gilead Sciences (US)
  155.       5.2.8.1 Financial Overview
  156.       5.2.8.2 Products Offered
  157.       5.2.8.3 Key Developments
  158.       5.2.8.4 SWOT Analysis
  159.       5.2.8.5 Key Strategies
  160.     5.2.9 Eli Lilly and Company (US)
  161.       5.2.9.1 Financial Overview
  162.       5.2.9.2 Products Offered
  163.       5.2.9.3 Key Developments
  164.       5.2.9.4 SWOT Analysis
  165.       5.2.9.5 Key Strategies
  166.   5.3 Appendix
  167.     5.3.1 References
  168.     5.3.2 Related Reports
  169. 6 LIST OF FIGURES
  170.   6.1 MARKET SYNOPSIS
  171.   6.2 NORTH AMERICA MARKET ANALYSIS
  172.   6.3 US MARKET ANALYSIS BY DRUG TYPE
  173.   6.4 US MARKET ANALYSIS BY MANUFACTURER TYPE
  174.   6.5 US MARKET ANALYSIS BY TYPE OF SYNTHESIS
  175.   6.6 US MARKET ANALYSIS BY INDICATION
  176.   6.7 CANADA MARKET ANALYSIS BY DRUG TYPE
  177.   6.8 CANADA MARKET ANALYSIS BY MANUFACTURER TYPE
  178.   6.9 CANADA MARKET ANALYSIS BY TYPE OF SYNTHESIS
  179.   6.10 CANADA MARKET ANALYSIS BY INDICATION
  180.   6.11 EUROPE MARKET ANALYSIS
  181.   6.12 GERMANY MARKET ANALYSIS BY DRUG TYPE
  182.   6.13 GERMANY MARKET ANALYSIS BY MANUFACTURER TYPE
  183.   6.14 GERMANY MARKET ANALYSIS BY TYPE OF SYNTHESIS
  184.   6.15 GERMANY MARKET ANALYSIS BY INDICATION
  185.   6.16 UK MARKET ANALYSIS BY DRUG TYPE
  186.   6.17 UK MARKET ANALYSIS BY MANUFACTURER TYPE
  187.   6.18 UK MARKET ANALYSIS BY TYPE OF SYNTHESIS
  188.   6.19 UK MARKET ANALYSIS BY INDICATION
  189.   6.20 FRANCE MARKET ANALYSIS BY DRUG TYPE
  190.   6.21 FRANCE MARKET ANALYSIS BY MANUFACTURER TYPE
  191.   6.22 FRANCE MARKET ANALYSIS BY TYPE OF SYNTHESIS
  192.   6.23 FRANCE MARKET ANALYSIS BY INDICATION
  193.   6.24 RUSSIA MARKET ANALYSIS BY DRUG TYPE
  194.   6.25 RUSSIA MARKET ANALYSIS BY MANUFACTURER TYPE
  195.   6.26 RUSSIA MARKET ANALYSIS BY TYPE OF SYNTHESIS
  196.   6.27 RUSSIA MARKET ANALYSIS BY INDICATION
  197.   6.28 ITALY MARKET ANALYSIS BY DRUG TYPE
  198.   6.29 ITALY MARKET ANALYSIS BY MANUFACTURER TYPE
  199.   6.30 ITALY MARKET ANALYSIS BY TYPE OF SYNTHESIS
  200.   6.31 ITALY MARKET ANALYSIS BY INDICATION
  201.   6.32 SPAIN MARKET ANALYSIS BY DRUG TYPE
  202.   6.33 SPAIN MARKET ANALYSIS BY MANUFACTURER TYPE
  203.   6.34 SPAIN MARKET ANALYSIS BY TYPE OF SYNTHESIS
  204.   6.35 SPAIN MARKET ANALYSIS BY INDICATION
  205.   6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG TYPE
  206.   6.37 REST OF EUROPE MARKET ANALYSIS BY MANUFACTURER TYPE
  207.   6.38 REST OF EUROPE MARKET ANALYSIS BY TYPE OF SYNTHESIS
  208.   6.39 REST OF EUROPE MARKET ANALYSIS BY INDICATION
  209.   6.40 APAC MARKET ANALYSIS
  210.   6.41 CHINA MARKET ANALYSIS BY DRUG TYPE
  211.   6.42 CHINA MARKET ANALYSIS BY MANUFACTURER TYPE
  212.   6.43 CHINA MARKET ANALYSIS BY TYPE OF SYNTHESIS
  213.   6.44 CHINA MARKET ANALYSIS BY INDICATION
  214.   6.45 INDIA MARKET ANALYSIS BY DRUG TYPE
  215.   6.46 INDIA MARKET ANALYSIS BY MANUFACTURER TYPE
  216.   6.47 INDIA MARKET ANALYSIS BY TYPE OF SYNTHESIS
  217.   6.48 INDIA MARKET ANALYSIS BY INDICATION
  218.   6.49 JAPAN MARKET ANALYSIS BY DRUG TYPE
  219.   6.50 JAPAN MARKET ANALYSIS BY MANUFACTURER TYPE
  220.   6.51 JAPAN MARKET ANALYSIS BY TYPE OF SYNTHESIS
  221.   6.52 JAPAN MARKET ANALYSIS BY INDICATION
  222.   6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG TYPE
  223.   6.54 SOUTH KOREA MARKET ANALYSIS BY MANUFACTURER TYPE
  224.   6.55 SOUTH KOREA MARKET ANALYSIS BY TYPE OF SYNTHESIS
  225.   6.56 SOUTH KOREA MARKET ANALYSIS BY INDICATION
  226.   6.57 MALAYSIA MARKET ANALYSIS BY DRUG TYPE
  227.   6.58 MALAYSIA MARKET ANALYSIS BY MANUFACTURER TYPE
  228.   6.59 MALAYSIA MARKET ANALYSIS BY TYPE OF SYNTHESIS
  229.   6.60 MALAYSIA MARKET ANALYSIS BY INDICATION
  230.   6.61 THAILAND MARKET ANALYSIS BY DRUG TYPE
  231.   6.62 THAILAND MARKET ANALYSIS BY MANUFACTURER TYPE
  232.   6.63 THAILAND MARKET ANALYSIS BY TYPE OF SYNTHESIS
  233.   6.64 THAILAND MARKET ANALYSIS BY INDICATION
  234.   6.65 INDONESIA MARKET ANALYSIS BY DRUG TYPE
  235.   6.66 INDONESIA MARKET ANALYSIS BY MANUFACTURER TYPE
  236.   6.67 INDONESIA MARKET ANALYSIS BY TYPE OF SYNTHESIS
  237.   6.68 INDONESIA MARKET ANALYSIS BY INDICATION
  238.   6.69 REST OF APAC MARKET ANALYSIS BY DRUG TYPE
  239.   6.70 REST OF APAC MARKET ANALYSIS BY MANUFACTURER TYPE
  240.   6.71 REST OF APAC MARKET ANALYSIS BY TYPE OF SYNTHESIS
  241.   6.72 REST OF APAC MARKET ANALYSIS BY INDICATION
  242.   6.73 SOUTH AMERICA MARKET ANALYSIS
  243.   6.74 BRAZIL MARKET ANALYSIS BY DRUG TYPE
  244.   6.75 BRAZIL MARKET ANALYSIS BY MANUFACTURER TYPE
  245.   6.76 BRAZIL MARKET ANALYSIS BY TYPE OF SYNTHESIS
  246.   6.77 BRAZIL MARKET ANALYSIS BY INDICATION
  247.   6.78 MEXICO MARKET ANALYSIS BY DRUG TYPE
  248.   6.79 MEXICO MARKET ANALYSIS BY MANUFACTURER TYPE
  249.   6.80 MEXICO MARKET ANALYSIS BY TYPE OF SYNTHESIS
  250.   6.81 MEXICO MARKET ANALYSIS BY INDICATION
  251.   6.82 ARGENTINA MARKET ANALYSIS BY DRUG TYPE
  252.   6.83 ARGENTINA MARKET ANALYSIS BY MANUFACTURER TYPE
  253.   6.84 ARGENTINA MARKET ANALYSIS BY TYPE OF SYNTHESIS
  254.   6.85 ARGENTINA MARKET ANALYSIS BY INDICATION
  255.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG TYPE
  256.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY MANUFACTURER TYPE
  257.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF SYNTHESIS
  258.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION
  259.   6.90 MEA MARKET ANALYSIS
  260.   6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG TYPE
  261.   6.92 GCC COUNTRIES MARKET ANALYSIS BY MANUFACTURER TYPE
  262.   6.93 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF SYNTHESIS
  263.   6.94 GCC COUNTRIES MARKET ANALYSIS BY INDICATION
  264.   6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG TYPE
  265.   6.96 SOUTH AFRICA MARKET ANALYSIS BY MANUFACTURER TYPE
  266.   6.97 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF SYNTHESIS
  267.   6.98 SOUTH AFRICA MARKET ANALYSIS BY INDICATION
  268.   6.99 REST OF MEA MARKET ANALYSIS BY DRUG TYPE
  269.   6.100 REST OF MEA MARKET ANALYSIS BY MANUFACTURER TYPE
  270.   6.101 REST OF MEA MARKET ANALYSIS BY TYPE OF SYNTHESIS
  271.   6.102 REST OF MEA MARKET ANALYSIS BY INDICATION
  272.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  273.   6.104 RESEARCH PROCESS OF MRFR
  274.   6.105 DRO ANALYSIS OF HEALTHCARE
  275.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  276.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  277.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  278.   6.109 HEALTHCARE, BY DRUG TYPE, 2024 (% SHARE)
  279.   6.110 HEALTHCARE, BY DRUG TYPE, 2024 TO 2035 (USD Billion)
  280.   6.111 HEALTHCARE, BY MANUFACTURER TYPE, 2024 (% SHARE)
  281.   6.112 HEALTHCARE, BY MANUFACTURER TYPE, 2024 TO 2035 (USD Billion)
  282.   6.113 HEALTHCARE, BY TYPE OF SYNTHESIS, 2024 (% SHARE)
  283.   6.114 HEALTHCARE, BY TYPE OF SYNTHESIS, 2024 TO 2035 (USD Billion)
  284.   6.115 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
  285.   6.116 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion)
  286.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  287. 7 LIST OF TABLES
  288.   7.1 LIST OF ASSUMPTIONS
  289.     7.1.1
  290.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  291.     7.2.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  292.     7.2.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  293.     7.2.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  294.     7.2.4 BY INDICATION, 2025-2035 (USD Billion)
  295.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  296.     7.3.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  297.     7.3.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  298.     7.3.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  299.     7.3.4 BY INDICATION, 2025-2035 (USD Billion)
  300.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  301.     7.4.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  302.     7.4.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  303.     7.4.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  304.     7.4.4 BY INDICATION, 2025-2035 (USD Billion)
  305.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  306.     7.5.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  307.     7.5.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  308.     7.5.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  309.     7.5.4 BY INDICATION, 2025-2035 (USD Billion)
  310.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  311.     7.6.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  312.     7.6.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  313.     7.6.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  314.     7.6.4 BY INDICATION, 2025-2035 (USD Billion)
  315.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  316.     7.7.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  317.     7.7.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  318.     7.7.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  319.     7.7.4 BY INDICATION, 2025-2035 (USD Billion)
  320.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  321.     7.8.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  322.     7.8.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  323.     7.8.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  324.     7.8.4 BY INDICATION, 2025-2035 (USD Billion)
  325.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  326.     7.9.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  327.     7.9.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  328.     7.9.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  329.     7.9.4 BY INDICATION, 2025-2035 (USD Billion)
  330.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  331.     7.10.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  332.     7.10.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  333.     7.10.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  334.     7.10.4 BY INDICATION, 2025-2035 (USD Billion)
  335.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  336.     7.11.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  337.     7.11.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  338.     7.11.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  339.     7.11.4 BY INDICATION, 2025-2035 (USD Billion)
  340.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  341.     7.12.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  342.     7.12.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  343.     7.12.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  344.     7.12.4 BY INDICATION, 2025-2035 (USD Billion)
  345.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  346.     7.13.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  347.     7.13.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  348.     7.13.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  349.     7.13.4 BY INDICATION, 2025-2035 (USD Billion)
  350.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  351.     7.14.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  352.     7.14.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  353.     7.14.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  354.     7.14.4 BY INDICATION, 2025-2035 (USD Billion)
  355.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  356.     7.15.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  357.     7.15.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  358.     7.15.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  359.     7.15.4 BY INDICATION, 2025-2035 (USD Billion)
  360.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  361.     7.16.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  362.     7.16.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  363.     7.16.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  364.     7.16.4 BY INDICATION, 2025-2035 (USD Billion)
  365.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  366.     7.17.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  367.     7.17.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  368.     7.17.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  369.     7.17.4 BY INDICATION, 2025-2035 (USD Billion)
  370.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  371.     7.18.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  372.     7.18.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  373.     7.18.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  374.     7.18.4 BY INDICATION, 2025-2035 (USD Billion)
  375.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  376.     7.19.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  377.     7.19.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  378.     7.19.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  379.     7.19.4 BY INDICATION, 2025-2035 (USD Billion)
  380.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  381.     7.20.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  382.     7.20.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  383.     7.20.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  384.     7.20.4 BY INDICATION, 2025-2035 (USD Billion)
  385.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  386.     7.21.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  387.     7.21.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  388.     7.21.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  389.     7.21.4 BY INDICATION, 2025-2035 (USD Billion)
  390.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  391.     7.22.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  392.     7.22.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  393.     7.22.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  394.     7.22.4 BY INDICATION, 2025-2035 (USD Billion)
  395.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  396.     7.23.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  397.     7.23.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  398.     7.23.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  399.     7.23.4 BY INDICATION, 2025-2035 (USD Billion)
  400.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  401.     7.24.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  402.     7.24.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  403.     7.24.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  404.     7.24.4 BY INDICATION, 2025-2035 (USD Billion)
  405.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  406.     7.25.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  407.     7.25.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  408.     7.25.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  409.     7.25.4 BY INDICATION, 2025-2035 (USD Billion)
  410.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  411.     7.26.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  412.     7.26.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  413.     7.26.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  414.     7.26.4 BY INDICATION, 2025-2035 (USD Billion)
  415.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  416.     7.27.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  417.     7.27.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  418.     7.27.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  419.     7.27.4 BY INDICATION, 2025-2035 (USD Billion)
  420.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  421.     7.28.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  422.     7.28.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  423.     7.28.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  424.     7.28.4 BY INDICATION, 2025-2035 (USD Billion)
  425.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  426.     7.29.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  427.     7.29.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  428.     7.29.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  429.     7.29.4 BY INDICATION, 2025-2035 (USD Billion)
  430.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  431.     7.30.1 BY DRUG TYPE, 2025-2035 (USD Billion)
  432.     7.30.2 BY MANUFACTURER TYPE, 2025-2035 (USD Billion)
  433.     7.30.3 BY TYPE OF SYNTHESIS, 2025-2035 (USD Billion)
  434.     7.30.4 BY INDICATION, 2025-2035 (USD Billion)
  435.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  436.     7.31.1
  437.   7.32 ACQUISITION/PARTNERSHIP
  438.     7.32.1

Healthcare Market Segmentation

Healthcare By Drug Type (USD Billion, 2025-2035)

  • Innovative Oncology APIs
  • Generic Oncology APIs

Healthcare By Manufacturer Type (USD Billion, 2025-2035)

  • Captive Manufacturer
  • Merchant Manufacturer

Healthcare By Type of Synthesis (USD Billion, 2025-2035)

  • Synthetic Oncology APIs
  • Biotech Oncology APIs

Healthcare By Indication (USD Billion, 2025-2035)

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Liver Cancer
  • Cervical Cancer
  • Others

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions